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OBJECTIVES: The objective of the study was to evaluate the budget impact of shift-
ing the treatment formenorrhagia in Canadian hospitals from rollerball to thermal
balloon ablation. Thermal balloon ablation procedures can be completed in an
ambulatory care setting as compared to rollerball procedures, which must be car-
ried out in the operating room. The aim of this study was to determine whether
shifting procedures from rollerball to thermal balloon ablation would present a
hospital with cost savings on a per patient basis. METHODS: A budget impact
model was created and populated using case-costing data from several large Ca-
nadian hospitals. The two procedures were compared in terms of device cost, use
of resources and nursing costs. The cost of treatment using rollerball and thermal
balloon ablationwere compared to determine the number of procedures that could
be completed using each device for the same total cost. RESULTS: Based on model
calculations the total cost per patient to treat menorrhagia using rollerball is
$1,977.58 and the total cost per patient to treat menorrhagia using thermal balloon
ablation is $1,415.46. The use of thermal balloon ablation allows for a hospital
savings of $562.12 per patient treated. The use of thermal balloon ablation would
enable a Canadian hospital to treat approximately 70 patients with menorrhagia
for the same total cost as treating 50 patients with rollerball. CONCLUSIONS: The
use of thermal balloon ablation for the treatment of menorrhagia allows for a cost
savings per patient when compared with rollerball.
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OBJECTIVES: Use of vascular closure devices for sealing the femoral artery follow-
ing percuatneous coronary diagnostic and interventional procedures has become a
routine practice. The collagen-based closure device system Angio-Seal™ has been
shown to be effective in decreasing time to hemostasis after coronary procedures.
Budgetary impact of replacing manual compression with Angio-Seal™, however,
has not been explored. We sought to evaluate the budget impact of using Angio-
Seal™ from the hospital perspective as it relates to clinical and economic
outcomes. METHODS: A customizable Excel®-based budget impact model was
built from a hospital perspective for a hypothetical cohort of 400 patients (200
interventional and 200 diagnostic) over a period of one year. Cost components
included device cost, facility cost (recover room costs) and nursing cost. A decision
treemodel was utilized to convert the expected probabilities of vascular complica-
tions into expected costs. Probabilities and costs were derived from published
meta-analyses and observational studies. Costs were converted to 2011 US dollars.
Sensitivity analysis was carried out over reported ranges of values formajor inputs
of the model. RESULTS: Using Angio-Seal™ in 100% of the cases resulted in esti-
mated cost savings of $255,498 per year compared to manual compression. Angio-
Seal™ usage resulted in cost savings for both interventional and diagnostic cases.
Cost savings were most sensitive to the variation in time and costs spent in the
recovery room as well as to the probabilities of groin bleeding and retroperitoneal
hemorrhage. Results were robust to changes in input variables. CONCLUSIONS:
Analysis shows that Angio-Seal™ represents a potential cost saving option for
institutions to achieve hemostasis after percutaneous coronary procedures with-
out increasing the risk of vascular complications. Given the current evidence on
safety and effectiveness of same-day discharge percutaneous coronary proce-
dures, Angio-Seal™ adds a potential cost savings dimension that can facilitate
adoption of this clinical practice.
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OBJECTIVES: Contrast agents for computer tomography (CT) are presented in glass
or plastic vials or syringes. Those containers take a lot of volume and are of con-
siderable weight resulting in important costs for storage and waste processing.
There is also a risk for injuries with sharp lips and spilling due to breakage. Those
containers need the use of small medical devices to allow injection of contrast
agents. The ScanBag® container was developed to overcome these problems. The
objectives of this study were to assess the impact on the hospital budget of using
Scanbag® instead of other containers. METHODS: According to the Ispor recom-
mendations for budget impact models (BIMs), we developed a BIM to demonstrate
the economical advantage of using contrast agents in ScanBag® from a hospital
perspective. Resource use in terms of broken products, injuries, storage, waste
management, small medical devices, and mono- or multipatient use for each pre-
sentation type were collected via literature and expert interviews in public and
private radiology centers in France, Belgium, Germany, Italy, Spain and the United
Kingdom. RESULTS: Replacing 1000 glass vials of 200 ml iobitridol by the same
volume in ScanBag® reduces broken products and injuries by 100%, storage space
by 43.8% and waste weight by 89.4%. Total cost savings for this simulation range
from €7076 in Germany to €8484 in Italy when costs of broken products, injuries,
storage, wastemanagement and small medical devices are considered. Depending
on the injector used, cost savings of up to €6,700 can be obtained for small medical
devices. CONCLUSIONS: Only in changing glass vials to ScanBag®, costs for hospi-
tals can be reduced through savings in broken products, injuries, storage andwaste
management. Largest cost savings are made on small medical devices.
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OBJECTIVES: Atrial fibrillation (AF) is a chronic, progressive disease characterized
by uncoordinated atrial activation involving rapid, irregular heartbeats (Fuster et
al. 2006). AF patients are likely to have co-morbidities such as congestive heart
failure (CHF) and stroke (Lee et al. 2008). The prevalence of AF in adults is 1% in
adults 55 years, but increases to as much as 10% by age 80 (Go et al. 2001). The
purpose of this study was to estimate the economic burden of AF in selected de-
veloping countries based on prevalence and direct health care costs. METHODS:
The economic burdens of AF in Brazil, China, India, Russia, and Turkey were cal-
culated based on prevalence rates identified via a literature search. Annual prob-
abilities for health care interventions and related costs (e.g.: management of AF,
stroke and CHF), and associated disability costs were included in the model. The
adult populationwas adjusted for the percentage of the populationwho had access
to health care. If cost data were unavailable, costs were imputed based on the ratio
of per capita health expenditures between the United States and country of inter-
est. Sensitivity analysis was performed for the health care accessible population.
RESULTS: The prevalence of AF in adults in the countries studied was: 226,000 in
Turkey; 430,000 in Brazil; 497,000 in Russia; 778,000 in India; and 1.8 million in
China. The estimated annual economic burden of AF was: 159 million in Turkey;
412 million in Brazil; 5.7 billion in Russia; 1.25 billion in India; and 2.5 billion in
China (2010 local currencies). Sensitivity analysis revealed that the results could be
substantially higher. CONCLUSIONS: The economic burden of AF in developing
countries is potentially substantial given the large populations in these countries.
Proper management of AF is becoming increasingly important in countries where
access to health care has constantly been improved.
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OBJECTIVES: Atrial fibrillation (AF) is an arrhythmia that progressively worsens
and is characterized by uncoordinated atrial activation involving a rapid and irreg-
ular heart rate (Fuster et al. 2006). AF patients are likely to have concomitant con-
gestive heart failure (CHF) and stroke (Lee et al. 2008). The prevalence of AF in
adults 65 years is 5 - 6%, increasing with age (Go et al. 2001). The purpose of this
study was to estimate the economic burden of AF in selected developed countries
based on prevalence and direct health care costs.METHODS:The economic burden
ofAF in theUnited States (US), Canada, Germany, France, UnitedKingdomand Italy
was modeled based on prevalence rates identified via a literature search. Annual
probabilities of receiving health care treatment and associated costs for AF, stroke
and CHF, and related disability costs were included in the model. If cost data were
unavailable, the costs were imputed based on the ratio of annual per capita health
expenditures between theUnited States and the country of interest. Cost estimates
were calculated in 2010 rates of the local currencies. RESULTS: The prevalence of
AF in adults aged 65 in the countries studied was: 172,000 in Canada; 328,000 in
theUnitedKingdom; 348,000 in France; 391,000 in Italy; 533,000 inGermany; and 1.6
million in the United States. The estimated annual economic burden of AFwas: 597
million in Canada; 596 million in the United Kingdom; 1.23 billion in France; 840
million in Italy; 1.58 billion in Germany; and 9.75 billion in the United States (2010
local currencies). CONCLUSIONS: The economic burden of AF in developed coun-
tries is substantial, and is expected to grow as the population ages. Early detection
and appropriate management of AF may help reduce this economic burden.
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OBJECTIVES: Atrial fibrillation (AF) is a chronic, progressive disease characterized
by uncoordinated atrial activation involving a rapid and irregular heartbeat (Fuster
et al. 2006). The prevalence of AF is1% in adults55 years old, but increases to as
much as 10% by age 80 (Go et al. 2001). The purpose of this studywas to forecast the
incidence of AF in selected countries for 2015, 2020 and 2025 based on predicted
prevalence. METHODS: The prevalence of AF in Brazil, Canada, China, India, the
United Kingdom and United States (US) was forecasted based on prevalence rates
identified via a literature search and 2010 estimates of AF prevalence. Population
forecasts for the selected countries were taken fromUnited Nations Department of
Economic and Social Affairs forecasts. The adult population was adjusted for the
percentage of the population with access to health care. The model assumed cur-
rent age-adjusted prevalence rates would remain constant through 2025. One-way
sensitivity analysis was performed for the health care accessible population and
the country forecasted population. RESULTS: The prevalence and economic bur-
den is forecasted to increase from 0% to 2% per year in the selected countries. In
2025, the prevalence and economic burden ranged from 282,000 and 245 million
Lira in Turkey to 2.68 million and $17 billion in the United States. The burden is
reported in 2010 local currencies. Sensitivity analyses revealed that prevalence in
developing countries were most affected by health care accessibility. In developed
countries, prevalence was most affected by forecasted population growth.
A64 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 – A 2 5 6
CONCLUSIONS: The prevalence of AF in selected countries was forecasted to grow
substantially in both developing and developed countries. As the world’s popula-
tion ages and health care becomesmore accessible, the economic burden of AFwill
continue to rise as well.
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OBJECTIVES: Estimate the expected number of catheter-related bloodstream infec-
tions (CRBSIs) and the associated costs derived from the adoption of a chlorhexi-
dine-impregnated sponge (Biopatch®) plus central venous catheter (CVC) tradi-
tional standard of care strategy in intensive care units (ICUs) versus CVC traditional
standard of care (no sponge) from a Mexican public hospital perspective.
METHODS: A decision tree was developed to estimate the clinical and economic
consequences of adding Biopatch® to CVC traditional standard of care in adult
population. ICUs’ annual catheter-days were estimated using local average occu-
pancy, number of placed catheters and length of stay published statistics. The
effectiveness variable was the CRBSI rate / 1000 catheter days, obtained from pub-
lished literature and used to estimate annual CRBSIs. It was assumed that once a
patient developed a CRBSI, he incurred in additional length of stay and received the
correspondent pharmacologic treatment; only one infection per patient was al-
lowed. Cost data were obtained from published literature and the public institu-
tion’s price data base; the cost for Biopatch® was internally assessed. The consid-
ered time horizonwas one year, thus no annual discount ratewas used. Costs were
inflation-adjusted and expressed in 2011Mexican pesos. Bivariate sensitivity anal-
yses were performed to assess uncertainty. RESULTS: The addition of Biopatch® to
CVC traditional standard of care in ICUs resulted in a 70% reduction of expected
annual CRBSIs and 0.8% less total costs when compared to the traditional standard
of care alone, thus representing a cost-saving alternative. Results were robust to
25% variations in the price of the sponge, ICU occupancy and CRBSI rates, even in
the extreme scenarios. CONCLUSIONS: The adoption of a Biopatch® plus CVC
traditional standard of care strategy in adult population at ICUs results in signifi-
cant clinical and economic benefits for the hospital, as it reduces CRBSI incidence
and resource utilization.
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OBJECTIVES: Published studies suggest that bypass therapy assay testing can be
used to effectively predict treatment response and dosing requirements for an
individual hemophilia patientwith inhibitors. This study aims to evaluate the costs
and treatment outcomes of bypass therapy assay testing versus no testing strategy
on different treatments for mild to moderate bleeding hemophilia patient with
inhibitors. This study also investigates the cost implications if testing assays could
predict the optimum dose for new type of therapies like concomitant therapy.
METHODS: A decision tree simulation model was used to simulate inhibitor treat-
ment costs and outcomes from a US third party payer perspective. All estimates of
costswere obtained from the literature or expert opinion andwere adjusted to 2011
US dollars. Based on a previous published model, the efficacy of APCC and rFVIIa
were assumed to be the same in the no testing scenario while assay testing was
assumed to improve the efficacy of both the products by 10%. Probabilistic sensi-
tivity analysis was used to determine the robustness of the model’s results. The
model was developed usingMicrosoft Excel and @Risk. RESULTS: If bypass therapy
assay testing successfully predicts the treatment response and improves treat-
ment efficacy by just 10%, cost savings of $6939 for APCC and $7699 for rFVIIa
treatment were observed per bleeding episode. Further, if testing successfully pre-
dicts the optimum dose for concomitant therapy on the onset of bleeding, signifi-
cant cost savings were observed when compared to rFVIIa and APCC therapies
alone. The results were sensitive to frequency of dosing, efficacy, rebleed rate and
drug price. CONCLUSIONS: Bypass therapy assay testing is recommended for re-
ducing costs while optimizing treatment response and dose before administering
treatment in hemophilia patients with inhibitors.
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OBJECTIVES: To compare cost of care among Type II diabetic patients using an
insulin pump delivery system versus alternate methods of insulin delivery (focus
on multiple daily injectors [MDIs]) using administrative claims data. METHODS:
This study used 2009MarketScan®ResearchDatabase data. Patientswere included
if they were continuously enrolled throughout 2009 and were classified as Type II
diabetic based on a combination of diagnosis codes andmedication claimswith the
final application of age where diagnosis was indeterminate. Patients were then
classified as MDIs and insulin pump users based on HCPCS codes and the use of
rapid or short acting insulin prescriptions. Treatment costs were the focus and
included pumps, pump supplies, insulin, and drugs. Costs of complications and
hospitalizations were not included. The study utilized a breakeven analysis to
capture both the fixed and variable costs associated with insulin pumps versus
injection across different cost percentiles of insulin and other drugs. RESULTS: A
total of 68,636 Type II diabetics met inclusion criteria, of which 84% (57,418) were
MDIs, and 16% (11,218) used insulin pumps. Durable insulin pumps required an
upfront investment of approximately $4200 with additional pump supply costs.
Insulin pump users, however, required less insulin and other drugs comparedwith
MDI patients, resulting in less associated costs. Insulin pumps last approximately
four years, and their value proposition increases with the level of insulin use re-
quired. Breakeven analysis revealed patients at the top 10th percentile of expen-
ditures for insulin and other drugs generated savings through lower use of insulin,
which offset the insulin pump cost in 3 years (1,071 days). CONCLUSIONS: Al-
though durable insulin pumps have an upfront cost, they are better able to control
insulin delivery. The reduced drug-related expenditures offset initial pump invest-
ment within three years for the most costly cohort of insulin users.
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OBJECTIVES: To estimate and compare the cost of arthroscopic subacromial de-
compression (SAD) using VAPR®VUE™Radiofrequency Systemwith COOLPULSE®
90 Electrode (COOLPULSE) and the ArthroCare® Quantum™ System with Super
TurboVac® electrode (Super TurboVac).METHODS: An in-vitro study of 72 bovine
tendon specimens was used with COOLPULSE 90 and Super TurboVac. These de-
vices were operated at their default ablation settings (220 and 270Watts for COOL-
PULSE and TurboVac, respectively) for multiple trials. The tissue removal rate was
determined by measuring the tissue mass before and after ablation. The measure
was repeated and averages were calculated. Average length of time needed for
tissue removal in SAD procedures and data on the unit cost of operation room (OR)
time were obtained from clinical model for arthroscopic procedure and published
literature. 2011 IMS data were used to calculate the average selling price for COOL-
PULSE and Super TurboVac. RESULTS: The in-vitro study showed the average ab-
lation rates for COOLPULSE (no clogs were found with COOLPULSE) and Super
TurboVac (excluding data from clogged runs for Super TurboVac) were 1.120.22
gram/minute and 0.930.21 gram/minute, respectively (p  0.001). Average time
for SAD from literature and clinical modeling was 13 minutes and the estimated
cost of OR time in the US was $20/minute. The average costs of ablation using
COOLPULSE and Super TurboVac were estimated to be $436 and $480, respectively.
CONCLUSIONS: Tissue removal rate in arthroscopic procedures is important for
surgical efficiency, for procedure duration that directly benefits patients, and for
cost. The in-vitro study demonstrated that COOLPULSE achieved significantly
higher tissue removal rates compared to Super TurboVac which may result in cost
savings to a surgery facility.
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OBJECTIVES: In December 2011, French health authorities agreed to reimburse the
explantation of defective Poly Implant Prothèse (PIP) breast implants, triggering
responses fromother national policymakers. Spurred by public concern andmedia
coverage, the UK health secretary announced that the National Healthcare Service
(NHS) would remove and replace the defective devices it had installed. Using the
UK as a case study, we evaluated three PIP-related policy scenarios that have been
instituted internationally. A cost comparision model was developed to assess the
cost implications of different explantation scenarios and to identify key cost driv-
ers from the perspective of the NHS.METHODS: The model explored the following
scenarios: (a) immediate removal of all PIP breast implants; (b) targeted removal of
ruptured implants; (c) symptom surveillance, with no extraordinary removal of
implants. Complication (e.g. rupture, silicone leakage) rates were taken from the
medical literature. Event management and screening costs were drawn from NHS
Reference Costs (2009-2010). Sensitivity analyses were conducted using a range of
costs, complication rates and patient numbers. RESULTS: Regardless of observed
rupture rates, reimbursing all explantations was the costliest option, followed by
screening and targeted removal of ruptured implants. Given the apparently low
rate of complications, the least costly optionwas a policy of symptom surveillance,
where explantation stemmed from presentation of rupture-related symptoms.
CONCLUSIONS: The dearth of implant-related complication data makes analysis
of the current crisis challenging. Until reliable data about the clinical implications
of the faulty implants are gathered, policymakerswill struggle to accurately assess
the relative budget impact of their recommendations. Even then, heterogeneity
among the devices exported to different countriesmay confound predictions.More
broadly, the lack of complication data highlighted by this study indicates a need for
improved regulation and monitoring of medical devices to ensure future policy
decisions are better informed.
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